手机版
帕金森病 Parkinson's disease
帕站首页 专题讨论 帕金森病 放心医生 中医与帕 病友故事 留言交流 脑起搏器 专家解答
 
第 1 2 页 (第1页,共16条)
东方:请教薛老 关于VK2的服用  邮箱:gslzqpf@yahoo.com.cn  IP:118.181.80.240  日期:2012-12-26 [回复1楼]

  请教薛老 关于VK2的服用
  薛老,您好,我看了您关于VK2的帖子,一直在当地买,还是没买到。最后在网上买到了。是美国产的,每片5mg,说明书都是英文,请教您,我们应该怎样服用?谢谢您!祝您和老伴舒心快乐!
   

薛传恽:回复1楼 东方  邮箱:xxuuee@gmail.com  IP:210.6.141.67  日期:2012-12-27 [回复2楼]

  回复1楼 东方
  回复1楼 东方:请教薛老 关于VK2的服用
  
  5mg一粒的量似乎大了。可以切开吗?我妻子吃0.1mg的。每天2-3粒。到底吃多少适合于帕症我也不清楚。因为过去没有人用于治疗帕症病人。大家摸索再交流吧。 

东方:回复2楼 薛传恽  邮箱:gslzqpf@yahoo.com.cn  IP:125.74.74.95  日期:2012-12-27 [回复3楼]

  回复2楼 薛传恽
  回复2楼 薛传恽:回复1楼 东方
  
  谢谢薛老!我试试再向您汇报情况! 

文静:VK2 的量  邮箱:jing.lotus@gmail.com  IP:83.84.6.78  日期:2012-12-27 [回复4楼]

  VK2 的量
  我给妈妈买的45mcg, 每天2次。因为从我们查到的资料知道,每天90mcg是安全的。 

东方:回复4楼 文静  邮箱:gslzqpf@yahoo.com.cn  IP:125.74.78.149  日期:2012-12-28 [回复5楼]

  回复4楼 文静
  回复4楼 文静:VK2 的量
  
  谢谢文静!现在关键是我不知道VK2的纯含量是多少。这就不好确定了,我讲的是每一粒是5mg,但是每一粒到底含多少纯VK2,还不得而知。说明书全部都是英文。请问文静你妈妈服用后效果如何?谢谢! 

fengsh:回复  邮箱:fengshu.ou@lntdisplayfj.com  IP:59.60.3.198  日期:2012-12-28 [回复6楼]

  回复
  你的5mg(毫克)应该就是纯含量5mg (毫克).
  文静 买的是 45ug(微克) 的,也就是纯含量45ug (微克). 

东方:回复6楼 fengsh  邮箱:gslzqpf@yahoo.com.cn  IP:125.74.78.149  日期:2012-12-28 [回复7楼]

  回复6楼 fengsh
  回复6楼 fengsh:回复
  
  谢谢!
  5mg=5000mcg是这样的换算吧
  
  在8月29日“有服用VK2效果的信息么”的帖子中中,undefi 先生的经验是:“正在用,我岳母原来服用的是多巴胺,美多巴。后来听说副作用大,帮她买了5mg含量和15毫克含量的,开始时用5mg,每次二粒,每天3次,效果不明显,后来用15毫克的,效果不错。”
  
  这个剂量可是大的很多啊!
  
  治病和保健用药量可能有差别的,但是能差这么大么?这一点我就很无知了!求助!! 

fengsh:回复  邮箱:fengshu.ou@lntdisplayfj.com  IP:59.60.3.198  日期:2012-12-28 [回复8楼]

  回复
  我觉得15mg 用量实在太大了,PD 是一个长期的抗争过程,我个人认为 用大剂量短疗程还不如用小剂量长疗程,讲究细水长流 水道渠成. ;另外VK 并未被实际证实能够治疗PD . 大剂量短时间内的所谓的 效果我觉得也有可能是其他因素导致的,并非全是VK 效果,存在一定的误判概率.
  而且任何事物 物极必反.摄入太多我想带来的潜在危害是否更大呢 ? 

东方:回复8楼 fengsh  邮箱:gslzqpf@yahoo.com.cn  IP:125.74.78.149  日期:2012-12-28 [回复9楼]

  回复8楼 fengsh
  回复8楼 fengsh:回复
  
  OK!
  
   

章华:回复8楼 fengsh  邮箱:drdanielcheung@gmail.com  IP:220.246.74.155  日期:2012-12-28 [回复10楼]

  回复8楼 fengsh
  回复8楼 fengsh:回复
  VitK2治疗帕金森症在剂量和疗效上没有一个共识,我仅探讨一个安全剂量和用于中老年帕症特别是女性病人的骨质疏松症(OP)的治疗。OP是老年女性帕症的常见病,会导致骨折,比如髋部(粗隆间或股骨颈骨折),Colles骨折(腕部)和脊柱压缩性骨折。
  日本是批准VitK2治疗骨质疏松症的,还有韩国和泰国,用的剂量是每天45mg,一般是分三次服用,安全程度和疗效比福善美等阿仑膦酸钠类药物更好,特别是脊椎部位骨密度的改善,当然还包括髋骨和手掌骨,以下是一个12个月的临床,还有36个月的。
  即使是每天45mg的VitK2也是安全的,所以我一般推荐每天3次,每次5mg.如果是检查出有严重骨质疏松的病人,就可以达到每天45mg.
  Menatetrenone即我们讲的VitK2.除了VitK2,也建议病友多晒太阳。
  Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency
  Y Sato1, Y Honda2, M Kaji3, T Asoh4, K Hosokawa1, I Kondo1, K Satoh5
  1 Department of Rehabilitation Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
  5 Department of Vascular Biology, Hirosaki University School of Medicine, Hirosaki, Japan
  2 Department of Neurology, Ohshima Hospital, Kita-Shigeyasu, Japan
  3 Department of Neurology, Kurume University Medical Center, Kurume, Japan
  4 Department of Internal Medicine, Futase Social Insurance Hospital, Iizuka, Japan
  
  Referred to byY. Sato, Y. Honda, M. Kaji, T. Asoh, K. Hosokawa, I. Kondo, K. Satoh
  Corrigendum to “Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s disease patients with vitamin D deficiency” [Bone 31 (2002) 114–118]
  
  Abstract
  Significant reduction in bone mineral density (BMD) occurs in patients with Parkinson’s disease (PD), correlating with immobilization and with vitamin D deficiency, and increasing the risk of hip fracture, especially in elderly women. As a biological indicator of compromised vitamin K status, an increased serum concentration of undercarboxylated osteocalcin (Oc) has been associated with reduced BMD in the hip and an increased risk of fracture in otherwise healthy elderly women. We evaluated treatment with vitamin K2 (menatetrenone; MK-4) in maintaining BMD and reducing the incidence of nonvertebral fractures in elderly female patients with PD. In a random and prospective study of PD patients, 60 received 45 mg of MK-4 daily for 12 months, and the remaining 60 (untreated group) did not. At baseline, patients of both groups showed vitamin D and K1 deficiencies, high serum levels of ionized calcium, and glutaminic residue (Glu) Oc, and low levels of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25-(OH)2D], indicating that immobilization-induced hypercalcemia inhibits renal synthesis of 1,25-(OH)2D and compensatory PTH secretion. BMD in the second metacarpals increased by 0.9% in the treated group and decreased by 4.3% in the untreated group (p < 0.0001). Vitamin K2 level increased by 259.8% in the treated group. Correspondingly, significant decreases in Glu Oc and calcium were observed in the treated group, in association with an increase in both PTH and 1,25-(OH)2D. Ten patients sustained fractures (eight at the hip and two at other sites) in the untreated group, and one hip fracture occurred among treated patients (p = 0.0082; odds ratio = 11.5). The treatment with MK-4 can increase the BMD of vitamin D- and K-deficient bone by increasing vitamin K concentration, and it can also decrease calcium levels through inhibition of bone resorption, resulting in an increase in 1,25-(OH)2D concentration.
  
  Keywords
  Fracture; Immobilization; Menatetrenone (MK-4); Osteoporosis; Parkinson’s disease (PD)
  
  --------------------------------------------------------------------------------
   

输1-2个字  第 1 2 页(共16条)